Direkt zum Inhalt

Weber, Florian ; Pavel, Vlad ; Müller, Martina ; Boor, Peter ; Läber, Lea ; von Stillfried, Saskia ; Buechler, Christa

Profiles of PCSK9, SREBP-2, and histopathology in COVID-19 and non-COVID-19 critical illness

Weber, Florian , Pavel, Vlad , Müller, Martina, Boor, Peter, Läber, Lea, von Stillfried, Saskia und Buechler, Christa (2025) Profiles of PCSK9, SREBP-2, and histopathology in COVID-19 and non-COVID-19 critical illness. BMC Infectious Diseases 25 (1).

Veröffentlichungsdatum dieses Volltextes: 19 Nov 2025 09:29
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.78158


Zusammenfassung

Background Severe illness caused by SARS-CoV-2 infection is associated with dysregulated cholesterol homeostasis. Proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates serum cholesterol levels, is induced in the plasma of patients with severe SARS-CoV-2 infection, compared to critically ill patients with other conditions. PCSK9 is primarily expressed in the liver, which is ...

Background
Severe illness caused by SARS-CoV-2 infection is associated with dysregulated cholesterol homeostasis. Proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates serum cholesterol levels, is induced in the plasma of patients with severe SARS-CoV-2 infection, compared to critically ill patients with other conditions. PCSK9 is primarily expressed in the liver, which is susceptible to damage during severe illness. Sterol regulatory element-binding protein 2 (SREBP-2) regulates PCSK9 expression, and higher activity of both PCSK9 and SREBP-2 is associated with liver injury and inflammation.
Methods
Liver tissues from 20 COVID-19 and 20 pre-pandemic autopsy cases were analysed, matched for age, sex, and intensive care treatment. Hepatic PCSK9 and SREBP-2 protein levels were assessed via immunohistochemistry. Histological scores for steatosis, fibrosis, and cholestasis were recorded. Additionally, plasma SREBP-2 levels were measured by ELISA in 25 septic COVID-19 and 34 septic non-COVID-19 patients.
Results
Across all cases, hepatocellular PCSK9 protein level was increased in the presence of cholestasis and positively correlated with hepatic SREBP-2 expression. No significant differences were observed between the COVID-19 and control groups regarding liver histology or hepatic PCSK9 and SREBP-2 protein levels. Plasma SREBP-2 levels were similar between COVID-19 and non-COVID-19 septic patients. Correlation analysis revealed positive associations between plasma SREBP-2, plasma PCSK9, and cholesteryl ester levels in the entire cohort, suggesting preserved SREBP-2 function during critical illness. Laboratory measures of liver disease in patients with and without SARS-CoV-2 infection were similar.
Conclusion
Critically ill patients with and without SARS-CoV-2 infection exhibit comparable hepatic expression of PCSK9 and SREBP-2, as well as similar liver histology and comparable levels of aminotransferases, bilirubin, and gamma-glutamyl transferase, which suggests that SARS-CoV-2 does not directly cause liver injury. As our cohort was small, this suggestion needs to be confirmed by studying larger groups.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftBMC Infectious Diseases
Verlag:Springer
Band:25
Nummer des Zeitschriftenheftes oder des Kapitels:1
Datum13 November 2025
InstitutionenMedizin > Lehrstuhl für Innere Medizin I
Medizin > Lehrstuhl für Pathologie
Identifikationsnummer
WertTyp
10.1186/s12879-025-12129-1DOI
Stichwörter / KeywordsSARS-CoV-2, Sepsis, PCSK9, SREBP-2, Cholestasis
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenZum Teil
URN der UB Regensburgurn:nbn:de:bvb:355-epub-781587
Dokumenten-ID78158

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben